Survodutide | 6mg

Survodutide (also known as BI 456906) is a dual glucagon receptor/GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma, showing promise in treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). 

Dual Agonist:

Survodutide activates both the glucagon and GLP-1 receptors, which are important for controlling metabolic functions. 

Mechanism of Action:

By targeting these two receptors, survodutide may help reduce appetite, promote fat oxidation, and improve glucose control. 

Development:

It's being developed as a potential treatment for obesity, overweight, and MASH. 

Administration:

It is administered once weekly via a subcutaneous injection. 

Clinical Trials and Results

Phase II Trial (MASH):

A Phase II trial in adults with MASH showed that survodutide significantly improved liver disease markers and fibrosis, with 83% of participants showing improvement. 

Phase II Trial (Obesity):

In a phase 2 dose-finding trial in patients with a BMI ≥27 kg/m2 and without diabetes, treatment with survodutide resulted in up to a mean 14.9% weight loss over 46 weeks. 

Phase III Trials:

Boehringer Ingelheim has launched three Phase III studies (SYNCHRONIZE-1, SYNCHRONIZE-2, and SYNCHRONIZE-CVOT) to further investigate the efficacy and safety of survodutide in people with obesity and overweight, with and without diabetes, cardiovascular disease, and chronic kidney disease. 

FDA Breakthrough Therapy Designation:

Survodutide has been granted a breakthrough therapy designation by the FDA for the treatment of non-cirrhotic MASH and moderate or advanced fibrosis in adults. 

Potential Benefits

Weight Loss: Survodutide has shown promise in reducing body weight in obese patients. 

Improvement in MASH: It has demonstrated the potential to improve liver disease markers and fibrosis in patients with MASH. 

Metabolic Improvements: It may improve glucose control, reduce fasting glycemia, and lower cholesterol levels. 

Batch SV24-056-001 99.3% purity | 6.58 mg

CAS No: 2805997-46-8

Molecular Formula: C192H289N47O61

Molecular Weight: 4231.62

Appearance: white powder

Storage: 2-8°

Purity: ≥99